Director Elliott Robinson filed a Form 4 with the SEC on November 6, 2026, disclosing sales of Hinge Health, Inc. (NYSE:HNGE) Class A Common Stock by affiliated Bessemer Venture Partners funds on November 4 and November 5, 2026.
Key Highlights
- Reporting person: Elliott Robinson, a director of Hinge Health, Inc., filing on behalf of Bessemer Venture Partners X L.P. (BVP X) and Bessemer Venture Partners X Institutional L.P. (BVP X Inst).
- Transaction dates: Sales occurred on November 4, 2026 (nine separate price tranches) and November 5, 2026 (at least two additional tranches disclosed in the filing).
- Price range on November 4: Weighted average prices per tranche ranged from $116.61 to $124.45, with individual transaction prices spanning $116.02 to $124.90, according to the filing.
- Price range on November 5: Weighted average prices per tranche ranged from $119.77 to $120.38, with individual transaction prices spanning $119.50 to $120.97, according to the filing.
- Largest single tranche on November 4: BVP X sold 18,269 shares and BVP X Inst sold 17,150 shares at a weighted average price of $121.35, in transactions ranging from $121.00 to $122.00.
- Beneficial ownership following transactions: The filing reports 0 shares beneficially owned following each reported transaction for all twelve line items.
- Ownership form: All reported holdings are indirect, with the nature of indirect beneficial ownership referenced in footnote 13 of the filing.
Bessemer Venture Partners Funds Execute Multi-Tranche Sales of Hinge Health Class A Shares
According to the Form 4 filed November 6, 2026, director Elliott Robinson reported that two affiliated entities, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P., disposed of Class A Common Stock of Hinge Health, Inc. (NYSE:HNGE) across twelve reported tranches over two trading days. All transactions carried the "S" transaction code, indicating open-market sales. The filing states that all shares were held and sold indirectly.
On November 4, 2026, the Bessemer Funds executed nine tranches at weighted average prices from $116.61 to $124.45. Among the larger tranches that day, BVP X sold 14,059 shares and BVP X Inst sold 13,197 shares at a weighted average price of $120.57, and BVP X sold 8,210 shares and BVP X Inst sold 7,708 shares at a weighted average of $119.61. The filing notes that each tranche involved multiple transactions across a stated price range, and that full per-price detail is available upon request to the issuer, any security holder, or SEC staff.
On November 5, 2026, the filing discloses at least two additional tranches. BVP X and BVP X Inst sold 1,825 and 1,712 shares, respectively, at a weighted average of $119.77, and 2,265 and 2,126 shares, respectively, at a weighted average of $120.38. Following each of the twelve reported transactions, the filing records beneficial ownership of 0 shares for each line item, with all ownership characterized as indirect.
What Was Disclosed
Director Elliott Robinson reported indirect sales of Hinge Health Class A Common Stock by Bessemer Venture Partners funds on November 4 and November 5, 2026, across multiple price tranches, with beneficial ownership shown as 0 following each transaction.



Please wait processing your request...